Prescient Therapeutics Ltd
ASX:PTX
Prescient Therapeutics Ltd
Interest Income Expense
Prescient Therapeutics Ltd
Interest Income Expense Peer Comparison
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Prescient Therapeutics Ltd
ASX:PTX
|
Interest Income Expense
-AU$18.7k
|
CAGR 3-Years
-55%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Immutep Ltd
ASX:IMM
|
Interest Income Expense
AU$2.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
14%
|
|
Mesoblast Ltd
ASX:MSB
|
Interest Income Expense
-$18.4m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
CSL Ltd
ASX:CSL
|
Interest Income Expense
-$469m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-25%
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Interest Income Expense
-AU$3.5m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-40%
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Interest Income Expense
-AU$733k
|
CAGR 3-Years
60%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Prescient Therapeutics Ltd's Interest Income Expense?
Interest Income Expense
-18.7k
AUD
Based on the financial report for Dec 31, 2023, Prescient Therapeutics Ltd's Interest Income Expense amounts to -18.7k AUD.
What is Prescient Therapeutics Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
-55%
The average annual Interest Income Expense growth rates for Prescient Therapeutics Ltd have been -55% over the past three years .